Dennis Kelly, MD
Interventional Cardiology · North Bergen, NJNPI 1417947748
Payments from drug & device makers
Across 546 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$836
- E.r. Squibb & Sons, L.L.C.$771
- Johnson & Johnson$734
- Merck$688
- Amarin Pharma, Inc.$674
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,980100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 110 | $1,103 |
| Amgen | 56 | $836 |
| E.r. Squibb & Sons, L.L.C. | 53 | $771 |
| Johnson & Johnson | 60 | $734 |
| Merck | 48 | $688 |
| Amarin Pharma, Inc. | 57 | $674 |
| AstraZeneca | 36 | $509 |
| Abiomed | 7 | $371 |
| Edwards Lifesciences | 5 | $330 |
| Pfizer | 21 | $315 |
| Kowa Pharmaceuticals America, Inc. | 16 | $212 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $208 |
| Boehringer Ingelheim | 12 | $169 |
| Boston Scientific | 2 | $169 |
| Medtronic | 1 | $121 |
| Esperion Therapeutics, Inc. | 7 | $102 |
| Heartflow, Inc. | 6 | $94 |
| Cvrx, Inc. | 5 | $87 |
| Novo Nordisk | 4 | $68 |
| Lexicon Pharmaceuticals, Inc. | 4 | $66 |
| Azurity Pharmaceuticals, Inc. | 3 | $46 |
| Abbott | 2 | $44 |
| Bayer | 2 | $41 |
| Cardiva Medical, Inc. | 2 | $38 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Bridgebio Pharma, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$149
- Emerge Push$145
- Resolute$121
- Repatha$109
How this compares
$8,020 in reported general payments places this provider in the 40th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 236 | $254,552 |
| Repatha SureclickEvolocumab | 72 | $95,250 |
| XareltoRivaroxaban | 52 | $74,840 |
| EntrestoSacubitril/Valsartan | 56 | $58,778 |
| JardianceEmpagliflozin | 52 | $51,936 |
| FarxigaDapagliflozin Propanediol | 60 | $50,927 |
| BrilintaTicagrelor | 49 | $34,898 |
| JanuviaSitagliptin Phosphate | 21 | $26,611 |
| VascepaIcosapent Ethyl | 45 | $20,857 |
| Praluent PenAlirocumab | 18 | $15,703 |
| LivaloPitavastatin Calcium | 15 | $8,984 |
| EdarbiAzilsartan Medoxomil | 22 | $8,332 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $8,093 |
| Atorvastatin Calcium | 470 | $5,869 |
| Metoprolol Succinate | 312 | $5,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $315 | $254,552236 claims |
| AstraZenecaFarxiga, Brilinta | $509 | $85,825109 claims |
| Johnson & JohnsonXarelto | $734 | $74,84052 claims |
| NovartisEntresto | $1,103 | $58,77856 claims |
| Boehringer IngelheimJardiance | $169 | $51,93652 claims |
| MerckJanuvia | $688 | $26,61121 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $37 | $16,42434 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $212 | $12,90737 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $13 | $2,52984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in North Bergen
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ramin HastingsHasbrouck Heights$355K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
- Darshan GodkarCedar Knolls$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.